Skip to content

Sperm Phenotype and Differentially Methylated Regions

Association Between Anogenital Distance, Sperm Phenotype and Epigenetics in Infertile Men.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05461079
Acronym
Epigenetics
Enrollment
60
Registered
2022-07-15
Start date
2017-11-01
Completion date
2023-12-31
Last updated
2024-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility, Male

Brief summary

Testicular dysgenesis syndrome (TDS) is known to cause epigenetic abnormalities in spermatozoa. Anogenital distance (AGD) is considered to be a suitable clinical marker of TDS, but the direct link between AGD and epigenetic abnormalities is still missing. Infertile men (n=10) presenting with shortened AGD and a control group of normal semen donors (n=10) with normal AGD will then be asked to provide one semen sample each. Using a flow cytometer and sorter (FACS) their spermatozoa will be sorted into populations of spermatozoa with/without DNA fragmentation or with/without chromatin decondensation. These sorted populations of spermatozoa will then be examined for differences in epigenetic imprinting differences using whole genome expression analysis. Whereas the sorting of spermatozoa will be carried out in Basel, the epigenetic analysis will be carried at the University of Geneva.

Detailed description

A subset of 10 men with shortened AGD (together with a control group of 10 fertile donors with normal AGD) will be asked to provide up to three semen samples, each of which then will be sorted with FACS into subpopulations with/without DNA fragmentation and into subpopulations with/without chromatin decondensation. Spermatozoa with fragmented DNA will be separated through FACS-sorting of spermatozoa with intact DNA using the YoPro 1-dye, which has been shown to correlate significantly with the degree of DNA fragmentation in the nuclei of sperm. In addition, spermatozoa with abnormal chromatin remodelling will be separated through sorting from spermatozoa with condensed chromatin using the fluorochrome chromomycin A3 (CMA3), which competes for protamin for binding to the minor groove of DNA thereby correlating with the persistence of histones in the sperm nuclei. Pilot experiments have demonstrated the highly significant and close correlation of CMA3 with anilin blue staining. Anilin blue staining is not suitable for the sorting experiment, because it requires fixation of the spermatozoa. Sorting based on CMA3 can be carried out with living spermatozoa. The sorted and anonymized samples will then be sent frozen in dry ice to a laboratory at the University of Geneva for the assessment of differences in the epigenetic imprinting of the DNA using whole genome expression studies.

Interventions

DIAGNOSTIC_TESTobtention of up to three semen samples

sorting of spermatozoa with flow cytometry. In the presence of insufficient numbers of spermatozoa after sorting (\<15 mill), up to three semen samples will be collected.

Sponsors

University of Geneva, Switzerland
CollaboratorOTHER
University of Basel
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
MALE
Age
20 Years to 55 Years

Inclusion criteria

* infertile men with known anogenital distance

Exclusion criteria

* sperm concentration must be more than 15 million/ml to allow appropriate sorting with flow cytometry...

Design outcomes

Primary

MeasureTime frameDescription
anogenital distance and epigenetics6 monthsnumber of differentially methylated transposable regulatory sequences in the genome of sorted spermatozoa.

Secondary

MeasureTime frameDescription
sperm phenotype 16 monthsbased on conventional semen analysis: concentration of spermatozoa (in mill/ml).
sperm phenotype 26 monthsbased on conventional semen analysis: progressive motility (in %).
sperm phenotype 36 monthsbased on conventional semen analysis: normal morphology (in %), staining).
sperm phenotype 46 monthschromatin decondensation (as given by % of CMA3 staining).
sperm phenotype 56 monthsDNA fragmentation (% of YoPro 1-staining).

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026